LifeStance Health Group, Inc. LFST
11.84
0.04
0.34%
as of 25 Sep
- Market cap
- $4.5B
- P/E
- 89.0×
Follow LFST
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
80.53 | 101.11 | 283.87 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.59 | 1.65 | 1.91 | 1.56 | |
P/FCF ratio |
23.62 | 17.30 | 24.70 | 17.83 | |
P/Operating CF |
41.11 | 74.51 | 47.21 | 78.00 | |
P/B ratio |
2.78 | 1.67 | 1.79 | 1.43 | |
Price to Tangible BV |
0.00 | 467.56 | 54.35 | 114.17 | |
EV/Sales |
2.61 | 1.70 | 1.92 | 1.60 | |
EV/EBITDA |
30.90 | 25.30 | 34.22 | 34.13 | |
EV/Operating CF |
19.00 | 13.90 | 18.71 | 14.54 | |
EV/FCF |
23.81 | 17.77 | 24.86 | 18.37 | |
Quick Ratio |
1.23 | 1.33 | 1.37 | 1.42 | |
Current Ratio |
1.38 | 1.48 | 1.65 | 1.58 | |
Net Debt/EBITDA |
0.73 | 1.89 | 0.54 | 3.09 | |
Debt/Assets |
11.87% | 12.23% | 12.07% | 12.54% | |
Debt/Equity |
0.18 | 0.18 | 0.17 | 0.18 | |
Asset Turnover |
0.73 | 0.70 | 0.66 | 0.64 | |
Operating CF/Net income |
4.23 | 2.32 | 4.93 | 25.34 | |
Capex/Depreciation |
(0.83) | (0.79) | (0.80) | (0.74) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
24.84% | 24.87% | 24.80% | 26.28% | |
Intangible Assets out of Total Assets |
0.68 | 0.69 | 0.67 | 0.69 | |
Share Based Compensation of Revenue |
4.54% | 3.77% | 4.37% | 5.03% | |
Graham Net Nets |
(0.08) | (0.13) | (0.10) | (0.14) | |
Graham Number |
3.40 | 2.33 | 1.48 | 0.00 | |
Earnings Yield |
1.24% | 0.99% | 0.35% | (0.46%) | |
Free Cash Flow Yield |
4.23% | 5.78% | 4.05% | 5.61% | |
Revenue per Share |
1.14 | 1.04 | 0.99 | 0.94 | |
Operating CF per Share |
0.26 | 0.09 | 0.15 | 0.07 | |
Capex per Share |
(0.03) | (0.03) | (0.03) | (0.03) | |
Free Cash Flow per Share |
0.23 | 0.06 | 0.12 | 0.04 | |
Cash per Share |
0.59 | 0.50 | 0.64 | 0.53 | |
Shareholders Equity per Share |
3.85 | 3.82 | 3.94 | 3.86 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.85 | 3.82 | 3.94 | 3.86 | |
Free Cash Flow |
87.92 | 22.34 | 46.65 | 17.00 | |
Working Capital |
103.21 | 116.18 | 164.24 | 131.82 | |
Capital Expenditures |
(11.99) | (10.77) | (10.91) | (10.29) | |
Net Current Asset Value |
(326.38) | (312.55) | (266.72) | (295.85) | |
EV/EBIT |
52.79 | 56.54 | 113.25 | 307.99 | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.03 | |
Net Profit Margin |
5.42% | 3.53% | 3.05% | 0.30% | |
Price to Operating Income |
52.37 | 55.03 | 112.54 | 298.79 | |
| Other line items | |||||
Average Receivables |
120.22 | 131.64 | 113.76 | 139.62 | |
Average Payables |
9.42 | 5.85 | 6.68 | 9.75 | |
Average Assets |
2,164.15 | 2,125.28 | 2,161.12 | 2,128.46 | |
Average Common Equity |
1,475.53 | 1,467.26 | 1,483.65 | 1,464.92 |
Columns are period end dates